Watch Ticker

Neumora Therapeutics, Inc. Common Stock

Go to Neumora Therapeutics, Inc. Common Stock Website

$1.64

-0.01 (-0.91%)

Live

Previous Close

$1.65

Day Range

$1.59 - $1.72

Previous Day Range

$1.62 - $1.79

Market Cap

$252.3 million USD

Day Vol.

865641

Previous Day Vol.

1.2 million

Currency

USD

Primary Exchange

None

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pip...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Helen Rubinstein - Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Neumora Therapeutics is initiating a Phase 1 clinical study for NMRA-861, a novel brain disease treatment with potential best-in-class pharmacology and no observed convulsions in pre-clinical studies.

Related tickers: NMRA.

Read Full Article

Nick Brandon, Ph.D. - Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

Neumora Therapeutics initiated a Phase 1 clinical study of NMRA-861, a positive allosteric modulator targeting M4 muscarinic receptors for potential schizophrenia treatment. The study aims to evaluate safety, tolerability, and pharmacokinetics in healthy adults and those with stable schizophrenia.

Related tickers: NMRA.

Read Full Article

Trending Tickers

Please sign in to view